Cloudbreak Pharma Submits FDA IND Application for CBT-358, Novel Dry Eye Disease Treatment Using SFA+ Technology 12
Cloudbreak Pharma Inc. - IND Submission for CBT-358: Busines...
Sign in to continue:
Cloudbreak Pharma Inc. - IND Submission for CBT-358: Busines...
Zhongyuan Bank Announces Upcoming Board Meeting – Potential ...
Phancy Group Q1 2026 Business Performance – Detailed Investo...
Scholar Education Group: Share Purchase Update Scholar...
Ruifeng Power Group Announces Strategic Collaboration in Und...
Shanghai Henlius Biotech Announces EMA Positive Opinion for ...
China Health Technology Group Announces Major Rights Issue: ...
China Health Technology Group Holding Company Limited - In-D...
CARsgen Therapeutics Issues Clarification Announcement on Sh...
ImmuneOnco Biopharmaceuticals Announces Redemption and New S...